A Rare Event of 5-Fluorouracil-Associated Peripheral Neuropathy

Me, Stein; Drumea, Keren; Yarnitsky, David; benny, Anila; Tzuk-Shina, Tzahala

doi:10.1097/00000421-199806000-00008

Cited by 30 publications

(12 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Stein reported two subjects who developed symptoms of pain and weakness in the lower extremities while receiving fluorouracil and levamisole [41]. EMG revealed axonal and demyelinting polyneuropathy involving small and large fibers.…”

Section: Discussionmentioning

confidence: 99%

Survey of oxaliplatin-associated neurotoxicity using an interview-based questionnaire in patients with metastatic colorectal cancer

et al. 2005

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Survey of oxaliplatin-associated neurotoxicity using an interview-based questionnaire in patients with metastatic colorectal cancer

et al. 2005

View full text Add to dashboard Cite

show abstract

“…Calcium was 9 mg/dL (8.3-10.3) and magnesium 1.7 mg/dL (1.5-2.4). Blood urea nitrogen (BUN) was 26 mg/dL (6)(7)(8)(9)(10)(11)(12)(13)(14)(15)(16)(17)(18)(19)(20)(21) and subsequently corrected to 10 mg/dL, while creatinine was 1 mg/dL (0.7-1.6). Serum lactate was 1.3 mg/dL (0.5-2.2) and serum ammonia 18 µg/dL .…”

Section: Discussionmentioning

confidence: 99%

Fluorouracil-Induced Neurotoxicity

2000

View full text Add to dashboard Cite

show abstract

“…Anyhow, the literature contains a small series of two patients experiencing neurotoxicity while they were receiving chemotherapy with 5-FU 114. Gemcitabine may occasionally evoke peripheral neuropathy with paresthesias and myalgias, whereas neurotoxicity rarely occurs while patients are treated with methotrexate, cytosine arabinoside (Ara-C), or topoisomerase inhibitors, such as irinotecan or topotecan 25…”

Section: Other Drugs Less Commonly Associated With Cipnmentioning

confidence: 99%

Chemotherapy-induced peripheral neuropathy in adults: a comprehensive update of the literature

Argyriou¹,

Kyritsis²,

Makatsoris³

et al. 2014

CMAR

243

217

View full text Add to dashboard Cite

Commonly used chemotherapeutic agents in oncology/hematology practice, causing toxic peripheral neuropathy, include taxanes, platinum compounds, vinca alkaloids, proteasome inhibitors, and antiangiogenic/immunomodulatory agents. This review paper intends to put together and discuss the spectrum of chemotherapy-induced peripheral neuropathy (CIPN) characteristics so as to highlight areas of future research to pursue on the topic. Current knowledge shows that the pathogenesis of CIPN still remains elusive, mostly because there are several sites of involvement in the peripheral nervous system. In any case, it is acknowledged that the dorsal root ganglia of the primary sensory neurons are the most common neural targets of CIPN. Both the incidence and severity of CIPN are clinically under- and misreported, and it has been demonstrated that scoring CIPN with common toxicity scales is associated with significant inter-observer variability. Only a proportion of chemotherapy-treated patients develop treatment-emergent and persistent CIPN, and to date it has been impossible to predict high-and low-risk subjects even within groups who receive the same drug regimen. This issue has recently been investigated in the context of pharmacogenetic analyses, but these studies have not implemented a proper methodological approach and their results are inconsistent and not really clinically relevant. As such, a stringent approach has to be implemented to validate that information. Another open issue is that, at present, there is insufficient evidence to support the use of any of the already tested chemoprotective agents to prevent or limit CIPN. The results of comprehensive interventions, including clinical, neurophysiological, and pharmacogenetic approaches, are expected to produce a consistent advantage for both doctors and patients and thus allow the registration and analysis of reliable data on the true characteristics of CIPN, eventually leading to potential preventive and therapeutic interventions.

show abstract

A Rare Event of 5-Fluorouracil-Associated Peripheral Neuropathy

Cited by 30 publications

References 6 publications

Survey of oxaliplatin-associated neurotoxicity using an interview-based questionnaire in patients with metastatic colorectal cancer

Survey of oxaliplatin-associated neurotoxicity using an interview-based questionnaire in patients with metastatic colorectal cancer

Fluorouracil-Induced Neurotoxicity

Chemotherapy-induced peripheral neuropathy in adults: a comprehensive update of the literature

Contact Info

Product

Resources

About